Halozyme Projects $1.71B–$1.81B Revenue by 2026 with New Subcutaneous Technologies

Halozyme has outlined a revenue target of $1.71 billion to $1.81 billion by 2026, driven by the expansion of its pipeline with new subcutaneous technologies.